デフォルト表紙
市場調査レポート
商品コード
1586431

特発性肺線維症治療市場、規模、シェア、動向、産業分析レポート:薬剤クラス別、投与経路別、流通チャネル別、地域別 - 市場予測、2025年~2034年

Idiopathic Pulmonary Fibrosis Treatment Market Size, Share, Trends, Industry Analysis Report: By Drug Class, Route of Administration, Distribution Channel, and Region - Market Forecast, 2025-2034


出版日
ページ情報
英文 118 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=154.26円
特発性肺線維症治療市場、規模、シェア、動向、産業分析レポート:薬剤クラス別、投与経路別、流通チャネル別、地域別 - 市場予測、2025年~2034年
出版日: 2024年10月01日
発行: Polaris Market Research
ページ情報: 英文 118 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Polaris Market Research社の最新調査によると、特発性肺線維症治療の世界市場規模は2034年までに78億1,000万米ドルに達する見込みです。この調査レポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

特発性肺線維症治療市場は、喫煙量の増加や座りっぱなしの行動などの生活習慣の変化、汚染物質への暴露の増加によって大きく牽引されています。これらの要因は、空気の質の低下や不健康な生活習慣が呼吸器の健康に影響を与えるため、IPFを含む肺疾患の罹患率の上昇に寄与しています。加えて、特発性肺線維症とその危険因子に対する認識の高まりは、早期診断と早期治療を促しています。ライフスタイルが進化し続ける中、効果的な特発性肺線維症治療薬に対する需要は今後数年で高まると予想されます。

特発性肺線維症の有病率の上昇が特発性肺線維症治療市場の成長を促進しています。米国国立衛生研究所によると、特発性肺線維症の有病率は2021年には人口10万人当たり36例でした。認知度の向上と診断方法の改善により、疾患の早期発見が容易になり、治療を求める患者層が拡大しています。その結果、特発性肺線維症の有病率の増加と診断法の進歩が相まって、効果的な治療オプションに対する需要が大幅に高まり、市場成長にプラスの影響を与えています。

特発性肺線維症は高齢者が特に罹患しやすい疾患であるため、世界的に老年人口が増加していることが、予測期間中に特発性肺線維症治療市場を大きく牽引すると予想されます。欧州連合(EU)では、人口の21.3%以上が65歳以上であり、効果的な治療に対する需要が高まっています。この人口動向は、特発性肺線維症治療に対するニーズの大幅な上昇につながる可能性が高いです。

特発性肺線維症治療市場レポート・ハイライト

投与経路別では、経口剤が予測期間中に世界市場で大きなCAGRを記録すると予測されています。この成長は、使いやすさや外来管理の可能性など、いくつかの利点によるものです。

流通チャネル別では、入院率の増加や高度な治療が必要な患者のための専門医療が利用可能であることから、病院薬局セグメントが2024年の市場で最大の収益シェアを占めました。

2024年、特発性肺線維症治療の世界市場において、医療インフラの先進性により北米が最大の収益シェアを占める

インドの特発性肺線維症治療市場は、医薬品製造部門への投資増加により、予測期間中に大きく成長すると予測されています。

世界の主要市場企業としては、F. Hoffmann-La Roche Ltd、Boehringer Ingelheim International GmbH、Bristol-Myers Squibb Company、Medicinova, Inc、Merck &Co, Inc、Galapagos NV、Novartis AG、Fibrogen, Inc.などが挙げられます。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界の特発性肺線維症治療市場の洞察

  • 市場スナップショット
  • 特発性肺線維症治療市場力学
    • 促進要因と機会
      • 高齢化人口の増加が市場の成長を牽引
      • 診断方法の進歩が市場規模を押し上げている
    • 抑制要因と課題
      • 限られた治療オプション
  • PESTEL分析
  • 特発性肺線維症治療市場の動向
  • バリューチェーン分析
  • COVID-19の影響分析

第5章 世界の特発性肺線維症治療市場:薬剤クラス別

  • 主な調査結果
  • イントロダクション
  • ピルフェニドン
  • ニンテダニブ
  • インターフェロンガンマト1b
  • その他

第6章 世界の特発性肺線維症治療市場:投与経路別

  • 主な調査結果
  • イントロダクション
  • オーラル
  • 注射可能
  • その他

第7章 世界の特発性肺線維症治療市場:流通チャネル別

  • 主な調査結果
  • イントロダクション
  • 病院薬局
  • 小売薬局
  • その他

第8章 世界の特発性肺線維症治療市場:地域別

  • 主な調査結果
  • イントロダクション
    • 特発性肺線維症治療市場評価:地域、2020年~2034年
  • 北米
    • 北米:薬剤クラス別、2020年~2034年
    • 北米:投与経路別、2020年~2034年
    • 北米:流通チャネル別、2020年~2034年
    • 米国
    • カナダ
  • 欧州
    • 欧州:薬剤クラス別、2020年~2034年
    • 欧州:投与経路別、2020年~2034年
    • 欧州:流通チャネル別、2020年~2034年
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • スペイン
    • オランダ
    • ロシア
    • その他欧州
  • アジア太平洋
    • アジア太平洋地域:薬剤クラス別、2020年~2034年
    • アジア太平洋地域:投与経路別、2020年~2034年
    • アジア太平洋地域:流通チャネル別、2020年~2034年
    • 中国
    • インド
    • マレーシア
    • 日本
    • インドネシア
    • 韓国
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ
    • 中東およびアフリカ:薬剤クラス別、2020年~2034年
    • 中東・アフリカ:投与経路別、2020年~2034年
    • 中東・アフリカ:流通チャネル別、2020年~2034年
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他中東とアフリカ
  • ラテンアメリカ
    • ラテンアメリカ:薬剤クラス別、2020年~2034年
    • ラテンアメリカ:投与経路別、2020年~2034年
    • ラテンアメリカ:流通チャネル別、2020年~2034年
    • メキシコ
    • ブラジル
    • アルゼンチン
    • その他ラテンアメリカ

第9章 競合情勢

  • 拡大と買収の分析
    • 拡大
    • 買収
  • 提携/協業/合意/公開

第10章 企業プロファイル

  • F. Hoffmann-La Roche Ltd
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Medicinova, Inc
  • Merck & Co., Inc.
  • Galapagos NV
  • Novartis AG
  • Fibrogen, Inc.
  • Avalyn Pharma Inc.
  • Promedior, Inc.
図表

List of Tables:

  • Table 1 Global Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 2 Global Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 3 Global Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 4 North America: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 5 North America: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 6 North America: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 7 U.S.: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 8 U.S.: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 9 U.S.: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 10 Canada: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 11 Canada: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 12 Canada: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 13 Europe: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 14 Europe: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 15 Europe: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 16 UK: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 17 UK: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 18 UK: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 19 France: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 20 France: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 21 France: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 22 Germany: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 23 Germany: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 24 Germany: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 25 Italy: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 26 Italy: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 27 Italy: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 28 Spain: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 29 Spain: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 30 Spain: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 31 Netherlands: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 32 Netherlands: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 33 Netherlands: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 34 Russia: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 35 Russia: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 36 Russia: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 37 Rest of Europe: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 38 Rest of Europe: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 39 Rest of Europe: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 40 Asia Pacific: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 41 Asia Pacific: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 42 Asia Pacific: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 43 China: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 44 China: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 45 China: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 46 India: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 47 India: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 48 India: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 49 Malaysia: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 50 Malaysia: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 51 Malaysia: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 52 Japan: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 53 Japan: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 54 Japan: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 55 Indonesia: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 56 Indonesia: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 57 Indonesia: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 58 South Korea: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 59 South Korea: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 60 South Korea: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 61 Australia: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 62 Australia: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 63 Australia: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 64 Rest of Asia Pacific: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 65 Rest of Asia Pacific: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 66 Rest of Asia Pacific: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 67 Middle East & Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 68 Middle East & Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 69 Middle East & Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 70 Saudi Arabia: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 71 Saudi Arabia: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 72 Saudi Arabia: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 73 UAE: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 74 UAE: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 75 UAE: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 76 Israel: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 77 Israel: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 78 Israel: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 79 South Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 80 South Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 81 South Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 82 Rest of Middle East & Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 83 Rest of Middle East & Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 84 Rest of Middle East & Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 85 Latin America: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 86 Latin America: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 87 Latin America: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 88 Mexico: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 89 Mexico: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 90 Mexico: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 91 Brazil: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 92 Brazil: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 93 Brazil: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 94 Argentina: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 95 Argentina: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 96 Argentina: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 97 Rest of Latin America: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 98 Rest of Latin America: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 99 Rest of Latin America: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • List of Figures:
  • Figure 1. Global Idiopathic Pulmonary Fibrosis Treatment Market, 2020-2034 (USD billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Price
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Drug Class
  • Figure 7. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2024 & 2034 (USD billion)
  • Figure 8. Market by Route of Administration
  • Figure 9. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2024 & 2034 (USD billion)
  • Figure 10. Market by Distribution Channel
  • Figure 11. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2024 & 2034 (USD billion)
  • Figure 12. Global Idiopathic Pulmonary Fibrosis Treatment Market Assessment, By Geography, 2020-2034 (USD billion)
  • Figure 13. Strategic Analysis - Global Idiopathic Pulmonary Fibrosis Treatment Market
目次
Product Code: PM5148

The global idiopathic pulmonary fibrosis treatment market size is expected to reach USD 7.81 billion by 2034, according to a new study by Polaris Market Research. The report "Idiopathic Pulmonary Fibrosis Treatment Market Size, Share, Trends, Industry Analysis Report: By Drug Class, Route of Administration, Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The idiopathic pulmonary fibrosis treatment market is significantly driven by changing lifestyle habits, such as rising smoking consumption and sedentary behavior, as well as increasing exposure to pollutants. These factors contribute to the rising incidence of lung diseases, including IPF, as poor air quality and unhealthy habits impact respiratory health. Additionally, the growing awareness of idiopathic pulmonary fibrosis and its risk factors encourages earlier diagnosis and treatment. As lifestyles continue to evolve, the demand for effective idiopathic pulmonary fibrosis therapies is expected to rise in the coming years.

The rising prevalence of idiopathic pulmonary fibrosis is driving the growth of the idiopathic pulmonary fibrosis treatment market. According to the National Institutes of Health, the prevalence of idiopathic pulmonary fibrosis was 36 cases per 100,000 people in 2021. The growing awareness and improving diagnostic methods facilitate earlier disease identification, expanding the patient population seeking treatment. Consequently, the combination of increasing idiopathic pulmonary fibrosis prevalence and advancements in diagnostics is significantly boosting demand for effective treatment options, positively impacting the market growth.

The growing number of geriatrics worldwide is expected to significantly drive the idiopathic pulmonary fibrosis treatment market during the forecast period, as older adults are particularly susceptible to the disease. In the European Union, over 21.3% of the population is aged 65 and older, highlighting the increasing demand for effective treatments. This demographic trend will likely lead to a substantial rise in the need for idiopathic pulmonary fibrosis therapies.

Idiopathic Pulmonary Fibrosis Treatment Market Report Highlights

Based on route of administration, the oral segment is anticipated to register a significant CAGR in the global market during the forecast period. This growth is attributed to its several advantages, including ease of use and potential of outpatient management.

By distribution channel, the hospital pharmacies segment accounted for the largest revenue share of the market in 2024 due to increasing hospitalization rates and the availability of specialized care for patients requiring advanced treatments.

In 2024, North America accounted for the largest revenue share of the global idiopathic pulmonary fibrosis treatment market due to its advanced medical infrastructure

The idiopathic pulmonary fibrosis treatment market in India is projected for significant growth during the forecast period due to the increased investments in its pharmaceutical manufacturing sector.

A few global key market players are F. Hoffmann-La Roche Ltd; Boehringer Ingelheim International GmbH; Bristol-Myers Squibb Company; Medicinova, Inc; Merck & Co., Inc.; Galapagos NV; Novartis AG; and Fibrogen, Inc.

Polaris Market Research has segmented the idiopathic pulmonary fibrosis treatment market report on the basis of drug class, route of administration, distribution channel, and region:

By Drug Class Outlook (Revenue - USD Billion, 2020-2034)

  • Pirfenidone
  • Nintedanib
  • Interferon Gammato1b
  • Others
  • By Route of Administration (Revenue - USD Billion, 2020-2034)
  • Oral
  • Injectable
  • Others
  • By Distribution Channel (Revenue - USD Billion, 2020-2034)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

By Regional Outlook (Revenue - USD Billion, 2020-2034)

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Australia
  • Rest of Asia Pacific
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
  • Rest of MEA

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Idiopathic Pulmonary Fibrosis Treatment Market Insights

  • 4.1. Idiopathic Pulmonary Fibrosis Treatment Market - Market Snapshot
  • 4.2. Idiopathic Pulmonary Fibrosis Treatment Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising Geriatric Population Are Driving Market Growth
      • 4.2.1.2. Advancement in Diagnostic Methods is Propelling Market Size
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Limited Treatment Options
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Idiopathic Pulmonary Fibrosis Treatment Market Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • 5.3. Pirfenidone
    • 5.3.1. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Pirfenidone, by Region, 2020-2034 (USD billion)
  • 5.4. Nintedanib
    • 5.4.1. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Nintedanib, by Region, 2020-2034 (USD billion)
  • 5.5. Interferon Gammato1b
    • 5.5.1. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Interferon Gammato1b, by Region, 2020-2034 (USD billion)
  • 5.6. Others
    • 5.6.1. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Others, by Region, 2020-2034 (USD billion)

6. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • 6.3. Oral
    • 6.3.1. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Oral, by Region, 2020-2034 (USD billion)
  • 6.4. Injectable
    • 6.4.1. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Injectable, by Region, 2020-2034 (USD billion)
  • 6.5. Others
    • 6.5.1. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Others, by Region, 2020-2034 (USD billion)

7. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • 7.3. Hospital Pharmacies
    • 7.3.1. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Hospital Pharmacies, by Region, 2020-2034 (USD billion)
  • 7.4. Retail Pharmacies
    • 7.4.1. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Retail Pharmacies, by Region, 2020-2034 (USD billion)
  • 7.5. Others
    • 7.5.1. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Others, by Region, 2020-2034 (USD billion)

8. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Geography

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Idiopathic Pulmonary Fibrosis Treatment Market Assessment, By Geography, 2020-2034 (USD billion)
  • 8.3. Idiopathic Pulmonary Fibrosis Treatment Market - North America
    • 8.3.1. North America: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
    • 8.3.2. North America: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
    • 8.3.3. North America: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.3.4. Idiopathic Pulmonary Fibrosis Treatment Market - U.S.
      • 8.3.4.1. U.S.: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.3.4.2. U.S.: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.3.4.3. U.S.: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.3.5. Idiopathic Pulmonary Fibrosis Treatment Market - Canada
      • 8.3.5.1. Canada: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.3.5.2. Canada: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.3.5.3. Canada: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • 8.4. Idiopathic Pulmonary Fibrosis Treatment Market - Europe
    • 8.4.1. Europe: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
    • 8.4.2. Europe: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
    • 8.4.3. Europe: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.4.4. Idiopathic Pulmonary Fibrosis Treatment Market - UK
      • 8.4.4.1. UK: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.4.4.2. UK: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.4.4.3. UK: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.4.5. Idiopathic Pulmonary Fibrosis Treatment Market - France
      • 8.4.5.1. France: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.4.5.2. France: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.4.5.3. France: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.4.6. Idiopathic Pulmonary Fibrosis Treatment Market - Germany
      • 8.4.6.1. Germany: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.4.6.2. Germany: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.4.6.3. Germany: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.4.7. Idiopathic Pulmonary Fibrosis Treatment Market - Italy
      • 8.4.7.1. Italy: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.4.7.2. Italy: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.4.7.3. Italy: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.4.8. Idiopathic Pulmonary Fibrosis Treatment Market - Spain
      • 8.4.8.1. Spain: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.4.8.2. Spain: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.4.8.3. Spain: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.4.9. Idiopathic Pulmonary Fibrosis Treatment Market - Netherlands
      • 8.4.9.1. Netherlands: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.4.9.2. Netherlands: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.4.9.3. Netherlands: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.4.10. Idiopathic Pulmonary Fibrosis Treatment Market - Russia
      • 8.4.10.1. Russia: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.4.10.2. Russia: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.4.10.3. Russia: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.4.11. Idiopathic Pulmonary Fibrosis Treatment Market - Rest of Europe
      • 8.4.11.1. Rest of Europe: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.4.11.2. Rest of Europe: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.4.11.3. Rest of Europe: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • 8.5. Idiopathic Pulmonary Fibrosis Treatment Market - Asia Pacific
    • 8.5.1. Asia Pacific: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
    • 8.5.2. Asia Pacific: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
    • 8.5.3. Asia Pacific: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.5.4. Idiopathic Pulmonary Fibrosis Treatment Market - China
      • 8.5.4.1. China: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.5.4.2. China: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.5.4.3. China: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.5.5. Idiopathic Pulmonary Fibrosis Treatment Market - India
      • 8.5.5.1. India: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.5.5.2. India: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.5.5.3. India: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.5.6. Idiopathic Pulmonary Fibrosis Treatment Market - Malaysia
      • 8.5.6.1. Malaysia: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.5.6.2. Malaysia: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.5.6.3. Malaysia: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.5.7. Idiopathic Pulmonary Fibrosis Treatment Market - Japan
      • 8.5.7.1. Japan: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.5.7.2. Japan: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.5.7.3. Japan: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.5.8. Idiopathic Pulmonary Fibrosis Treatment Market - Indonesia
      • 8.5.8.1. Indonesia: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.5.8.2. Indonesia: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.5.8.3. Indonesia: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.5.9. Idiopathic Pulmonary Fibrosis Treatment Market - South Korea
      • 8.5.9.1. South Korea: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.5.9.2. South Korea: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.5.9.3. South Korea: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.5.10. Idiopathic Pulmonary Fibrosis Treatment Market - Australia
      • 8.5.10.1. Australia: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.5.10.2. Australia: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.5.10.3. Australia: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.5.11. Idiopathic Pulmonary Fibrosis Treatment Market - Rest of Asia Pacific
      • 8.5.11.1. Rest of Asia Pacific: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.5.11.2. Rest of Asia Pacific: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.5.11.3. Rest of Asia Pacific: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • 8.6. Idiopathic Pulmonary Fibrosis Treatment Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
    • 8.6.2. Middle East & Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
    • 8.6.3. Middle East & Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.6.4. Idiopathic Pulmonary Fibrosis Treatment Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.6.4.2. Saudi Arabia: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.6.4.3. Saudi Arabia: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.6.5. Idiopathic Pulmonary Fibrosis Treatment Market - UAE
      • 8.6.5.1. UAE: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.6.5.2. UAE: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.6.5.3. UAE: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.6.6. Idiopathic Pulmonary Fibrosis Treatment Market - Israel
      • 8.6.6.1. Israel: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.6.6.2. Israel: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.6.6.3. Israel: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.6.7. Idiopathic Pulmonary Fibrosis Treatment Market - South Africa
      • 8.6.7.1. South Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.6.7.2. South Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.6.7.3. South Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.6.8. Idiopathic Pulmonary Fibrosis Treatment Market - Rest of Middle East & Africa
      • 8.6.8.1. Rest of Middle East & Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.6.8.2. Rest of Middle East & Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.6.8.3. Rest of Middle East & Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • 8.7. Idiopathic Pulmonary Fibrosis Treatment Market - Latin America
    • 8.7.1. Latin America: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
    • 8.7.2. Latin America: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
    • 8.7.3. Latin America: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.7.4. Idiopathic Pulmonary Fibrosis Treatment Market - Mexico
      • 8.7.4.1. Mexico: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.7.4.2. Mexico: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.7.4.3. Mexico: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.7.5. Idiopathic Pulmonary Fibrosis Treatment Market - Brazil
      • 8.7.5.1. Brazil: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.7.5.2. Brazil: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.7.5.3. Brazil: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.7.6. Idiopathic Pulmonary Fibrosis Treatment Market - Argentina
      • 8.7.6.1. Argentina: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.7.6.2. Argentina: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.7.6.3. Argentina: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.7.7. Idiopathic Pulmonary Fibrosis Treatment Market - Rest of Latin America
      • 8.7.7.1. Rest of Latin America: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.7.7.2. Rest of Latin America: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.7.7.3. Rest of Latin America: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. F. Hoffmann-La Roche Ltd
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Boehringer Ingelheim International GmbH
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Bristol-Myers Squibb Company
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Medicinova, Inc
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Merck & Co., Inc.
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Galapagos NV
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Novartis AG
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Fibrogen, Inc.
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Avalyn Pharma Inc.
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Promedior, Inc.
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development